Results 161 to 170 of about 10,513 (268)

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Negative effects of mindfulness-based cognitive therapy and cognitive behavioural analysis system of psychotherapy for patients with 'difficult to treat' depression: protocol for a systematic review and individual participant data meta-analysis. [PDF]

BMJ Open
Niemi M, Michalak J, Velana M, Barnhofer T, Harrer M.   +4 more
europepmc   +1 more source

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Exercise priming to enhance therapeutic bond and behavioral activation in CBT for MDD: a randomized controlled target-engagement trial with remission signal. [PDF]

J Affect Disord
Meyer JD, Kelly SJE, Gidley JM, Lansing JE, Smith SL, Churchill SL, Connolly ML, Thomas EBK, Goldberg SB, Abercrombie HC, Murray TA, Wade NG.   +11 more
europepmc   +1 more source

Therapeutic Factors in Group Psychotherapy [PDF]

Postgraduate Medical Journal, 1986
openaire   +1 more source

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source

A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial

Addiction, EarlyView.
Abstract Background and aims Individuals with opioid use disorder (OUD) frequently present with co‐occurring mental health conditions such as depression and posttraumatic stress disorder (PTSD), along with other mental health substance use disorders, physical health conditions and social determinants that together comprise ‘clinical complexity ...
Megan S. Schuler, Rebecca Weir, Colleen M. McCullough, Grace M. Hindmarch, Beth Ann Griffin, Kirsten Becker, Lisa S. Meredith, Katherine E. Watkins   +7 more
wiley   +1 more source

Regenerating Images in Memory (RIM): An Introduction for Therapists

Psychotherapy and Counselling Journal of Australia, 2018
Kenneth Cole
doaj   +1 more source

Rarity-Weighted Change Score: An Integrative, Distribution-Aware Measure of Pre-Post Outcomes in Psychotherapy Research. [PDF]

Cureus
Roopesh B.
europepmc   +1 more source

Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial

Addiction, EarlyView.
Abstract Aims To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24 ...
John Marsden, Mike Kelleher, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Eilish Gilvarry, Natalie Lowry, Luke Mitcheson, Robert Murray, Sophie Quarshie, Zoë Hoare   +11 more
wiley   +1 more source